Evidence · Randomised trial
Preoperative oral thyroid hormones to prevent euthyroid sick syndrome and attenuate myocardial ischemia-reperfusion injury after cardiac surgery with cardiopulmonary bypass in children: A randomized, double-blind, placebo-controlled trial.
- Cardiovascular
- Congenital heart disease
- Medical
- Renal and metabolic
This paper is from 2018, more than five years ago. Newer evidence may have been published since.
Summary
Single-centre randomised, double-blind, placebo-controlled pilot trial of preoperative oral thyroid hormone in 40 children aged 3-12 years undergoing elective congenital heart disease repair with cardiopulmonary bypass. Outcomes included perioperative thyroid hormone profiles, haemodynamics, extubation time, ICU stay, inotrope use and markers of myocardial ischaemia-reperfusion injury. The authors report attenuation of postoperative euthyroid sick syndrome and reduced myocardial injury markers, with no difference in haemodynamics, extubation time or ICU stay. Relevant to PICU teams managing postoperative cardiac patients, though small and single-centre.
Summary written for PICUlearn. Always read the original.
- Licence:
- Open (Creative Commons)
The full text of this openly licensed paper is available to PICUlearn members, and Peeky can answer questions from it.
Guidelines are shown for education. Follow your unit's own guidance and senior advice.